RxDoctor Payments Data

Brenda Moreland

Family · Oakland, MDNPI 1023521804

Payments from drug & device makers

$730in general payments, 2019–2025

Across 42 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$142
  • GSK$123
  • AstraZeneca$73
  • Abbott$67
  • Novo Nordisk$64
  • Lilly USA, LLC$57
  • plus $205 from 7 others

What the payments were for

  • Food & beverage$730100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$730 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$137,141
Medicare patients
497
Services billed
2,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$117,859
OzempicSemaglutide70$74,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$60,839
FarxigaDapagliflozin Propanediol55$55,929
XifaxanRifaximin14$47,478
MounjaroTirzepatide34$43,896
JardianceEmpagliflozin40$38,420
XareltoRivaroxaban27$36,058
TrulicityDulaglutide22$29,635
LinzessLinaclotide35$19,686
RybelsusSemaglutide17$18,337
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$18,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$13,872
Breo ElliptaFluticasone/Vilanterol18$10,844
Novolog FlexpenInsulin Aspart27$9,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$19$122,193130 claims
Novo NordiskOzempic, Rybelsus$64$92,56187 claims
Lilly USA, LLCMounjaro, Trulicity$57$73,53156 claims
GSKTrelegy Ellipta, Breo Ellipta$123$71,683109 claims
AstraZenecaFarxiga, Symbicort$73$59,15969 claims
AbbVieLinzess$36$19,68635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,843 family providers in Maryland.

Other family in Oakland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →